Sigilon Therapeutics — Corporate Update (May 2021)
21 slides from Sigilon Therapeutics's corporate update, May 10, 2021
Slide 1: Advancing Potential Functional Cures for Patients With Chronic Diseases
Advancing Potential Functional Cures for Patients With Chronic Diseases ©2021 Sigilon Therapeutics, Inc. May 2021
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Sigilon Therapeutics, Inc. (“we,” “us,” “our,” “Sigilon” or the “Company”) and is made for informational purposes only and not for any other purpose. Certain information contained in this presentation and statements made orally during this presentati
Slide 3: Company Overview
SHIELDED LIVING THERAPEUTICS PLATFORM Company Overview Our mission is to develop functional cures for patients living with a wide range of chronic diseases • Designed to overcome significant limitations of cell and gene therapies and drawbacks of current biologic-based therapies • Potential benefits
Slide 4: Modular SLTx Product Platform
+ + 1. The Cells Selection criteria based on: ✓ Safety ✓ Durability ✓ Scalability ✓ Engineerability Ability to switch transgene allows for plug-n-play 3 pillars of our modular platform technology Modular SLTx Product Platform From Cell Function to Potential Functional Cure 2. The Sphere 3. The Manuf
Slide 5: Our Company History
Our Company History 2018 – 2019 2016 - 2017 1980 - 2015 Sigilon created by Flagship Pioneering Foundational partnership Developed our modular platform Hemophilia A Orphan Drug Designation (FDA) Key publications in peer-reviewed journal, Nature Seminal work by Drs. Robert (Bob) Langer and Daniel Ande
Slide 6: 2020: A Transformational Year For Sigilon
2020: A Transformational Year For Sigilon ✓ Secured Series B financing of $105M ✓ Closed an upsized IPO (Dec 8, 2020), at a public offering price of $18.00 per share and aggregate gross proceeds were $144.9 million ✓ Dosed first patients in Phase 1/2 study of SIG-001 for Hem A ✓ Received 03 Orphan D
Slide 7: Robust Preclinical Programs
Robust Preclinical Programs ✓ 4-month NHP islets ✓ 12-month rat Islet in STZ mouse model ✓ 6 & 5-month NSG mice (SIG-001 and SIG-005) ✓ 6 & 12-month NHP (empty spheres) DURABILITY OF SLTX PLATFORM ✓ Product delivery method evaluated in mice, NHP and human cadavers ✓ Hem A, MPS-1, Fabry, FVII Def & H
Slide 8: SLTx Offers Many Important Potential Advantages Versus Other Modalities
SLTx Offers Many Important Potential Advantages Versus Other Modalities 7
Slide 9: SLTx Offers Important Potential Advantages Versus Gene Therapy
SLTx Offers Important Potential Advantages Versus Gene Therapy 8 Recent Gene Therapy Setbacks: ✓ Declining efficacy (including loss of all expression) ✓ Unpredictable overdosing ✓ Insertional mutagenesis risk with AAV (genotoxicity risk) ✓ Insertional mutagenesis risk with alkylating agents ✓ Seriou
Slide 10: Addressing a Broad Range Of Chronic Diseases
PROGRAM DISCOVERY LEAD OPTIMIZATION IND ENABLING PHASE 1/2 PHASE 3 Rare Blood Disorders SIG-001 – Hemophilia A SIG-009 – FVII Deficiency SIG-003 – Hemophilia B Lysosomal Diseases SIG-005 – MPS-1 SIG-007 – Fabry SIG-018 – MPS-2 SIG-020 – MPS-6 Endocrine & Other Chronic Diseases SIG-002 – Type 1 Diabe
Slide 11: SIG-001 for Hem A: Efficacy, Durability and Controllability Observed in Preclinical Studies
SIG-001 for Hem A: Efficacy, Durability and Controllability Observed in Preclinical Studies * -Statistically significant reduction in bleeding time relative to HA + wt (p<0.05). Bleeding time (in sec) W T HA + wt cells HA + SIG-001 0 500 1000 1500 2000 WT Mice HA Mice + Control Spheres HA Mice + SIG
Slide 12: SIG-001 Phase 1/2 Dose Escalation Study Represents Significant Milestone
SIG-001 Phase 1/2 Dose Escalation Study Represents Significant Milestone For SLTx Platform Rare Blood Disorders • Significant milestones for: • Product platform for our pipeline • GMP Manufacturing • Logistics of Fresh Product • Initial Safety Observations • Measurable plasma FVIII activity • Recent
Slide 13: SIG-005: Phenotypic Correction in Bone after Months of Treatment in Mice with MPS-1
SIG-005: Phenotypic Correction in Bone after 5 Months of Treatment in Mice with MPS-1 Reduced thickness in cortical areas Sustained reduction in GAGs Female Male 0 5 10 15 20 25 T r a b e c u l a , R e l a t i v e a m o u n t o f b o n e P=0.042 P=0.008 Reduction in bone volume Female Male 0 100 200
Slide 14: Reduction of Substrate in Tissues of MPS-1 Mice Months After SIG-005
Reduction of Substrate in Tissues of MPS-1 Mice 5 Months After SIG-005 Heart Kidney Liver Lung Treated Untreated Zeiss 20x; Alcian blue; Black arrow indicates substrate (Untx: G7-1; Tx: G3-1); * Glomerulus; * Bronchiole Lysosomal Diseases 13
Slide 15: Reduction Lyso-Gb3 Across Tissues Month After SIG-007 Administration in Mice with Fabry
Reduction Lyso-Gb3 Across Tissues 1 Month After SIG-007 Administration in Mice with Fabry Lysosomal Diseases Presented at the 17th Annual WORLDSymposium™ February 8th - 12th 2021, virtually. N=6/group; L:low dose; M: medium dose; H:high dose; Unt: untreated; unpaired t-test vs untreated: ****p<0.001
Slide 16: Sigilon and Lilly Collaborating to Develop Potential Functional Cure for Type 1 Diabetes
Sigilon and Lilly Collaborating to Develop Potential Functional Cure for Type 1 Diabetes • Sigilon is responsible for execution of the program through IND • Eli Lilly, a global leader in diabetes, will develop and commercialize program worldwide if approved • Financial Terms: • $75 million initial c
Slide 17: Diabetes Program Progresses Toward IND
Diabetes Program Progresses Toward IND Blood Glucose (mg/dL) Mean ± SEM 600 500 400 300 200 100 0 Time (Days) 600 500 400 300 200 100 0 330 300 270 240 210 180 150 120 90 60 30 0 Review Article by Langer R; Molecular Frontiers Journal (2017) Rat donor islets in STZ mice (12 months) Type 1 Diabetes 1
Slide 18: Sustained IL-10 Administration Protects Mice from Concanavalin-A Induced Liver Inflammation
Sustained IL-10 Administration Protects Mice from Concanavalin-A Induced Liver Inflammation 17 Liver Necrosis + + - + Concanavalin A Immune Mediated Diseases ❑ Autoimmune hepatitis: ▪ Hepatocyte destruction by pro-inflammatory cytokines ▪ Incidence is 1 to 2 per 100,00O and prevalence is about 24 pe
Slide 19: Pioneering an Innovative and Scalable Automated Encapsulation System
Pioneering an Innovative and Scalable Automated Encapsulation System Simpler process than other advanced therapies may lead to COGS on the order of mAbs 18
Slide 20: Multiple Milestones Targeted within months
Multiple Milestones Targeted within 24 months Filing a 2nd IND/CTA submission H1 21 •IND/CTA Submission: SIG-005/MPS-1 Initiating a 2nd Clinical Program H2 21 •Up to 9-month follow-up Phase 1/2 data (3 – 4 patients): SIG-001/Hem A •Complete enrollment of dose cohorts: SIG-001/Hem A Phase 1/2 •Phase
Slide 21: Thanks
sigilon therapeutics” Thanks